Results 71 to 80 of about 1,577 (196)

Immunotherapy for Leiomyosarcoma: Current Status and Perspectives

Journal of Immunology Research, Volume 2026, Issue 1, 2026.
Leiomyosarcoma (LMS), one of the soft‐tissue sarcomas (STSs), has a relatively higher risk of distant metastasis. This has resulted in current first‐line treatments still failing to deliver satisfactory outcomes, and the current treatment of LMS remains controversial and challenging.
Haoyue Qi, Hanxi Zhang, Qin Wang, Xiaolu Wang, Limei Min, Yingling Zhou, Baorui Liu, Rutian Li, Poorani Gurumallesh   +8 more
wiley   +1 more source

Figure S2 from Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments

, 2018
Low dose WT mIFN cannot prevent tumor growth, even when targeted to the tumor as an immunocytokine.
Thomas Wueest (14930538), Bart Vandekerckhove (517461), Franciane Paul (14930535), Geneviève Garcin (398609), Alexander Van Parys (208296), Yann Bordat (379386), Elke Rogge (451156), Annick Verhee (271601), Sandra Van Lint (14910185), Stefaan De Koker (10047073), Jan Tavernier (31436), Gilles Uzé (60667), José Van der Heyden (14930541), Niko Kley (14930544), Sarah Gerlo (327069), Anje Cauwels (451158), Dominiek Catteeuw (137303)   +16 more
core   +1 more source

Crosstalk Between Cancer‐Associated Fibroblasts and Immune Cells: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 4, Issue 4, December 2025.
Cancer‐associated fibroblasts (CAFs) are widely engaged in tumor progression in the tumor microenvironment. CAFs interact actively with immunocytes including tumor‐associated macrophages, T cells, neutrophils, and NK cells in a positive‐feedback loop to sculpt tumor immune microenvironment and participate in tumor activities and antitumor therapy ...
Ya Li, Xingpeng Di, Jiawei Chen, Jingwen Wei, Tianyue Li, Kunjie Wang, Banghua Liao, Deyi Luo   +7 more
wiley   +1 more source

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12

, 2010
Proinflammatory cytokines have been used for several years in patients with advanced cancer but their adminis-tration is typically associated with severe toxicity hamper-ing their application to therapeutically active regimens.
Sommavilla, Roberto, Pasche, Nadine, Dario Neri, Giovannoni, Leonardo, Nadine Pasche, Trachsel, Eveline, Neri, Dario; id_orcid, Roesli, Christoph, Kaspar, Manuela, Villa, Alessandra, Manuela Kaspar, Ra Villa, Alessandra Villa, Eveline Trachsel, Leonardo Giovannoni, Christoph Roesli, Roberto Sommavilla, Giovannoni L, Villa A, Neri D, Sommavilla R, Pasche N, Kaspar M, Trachsel E, Roesli C   +24 more
core   +1 more source

The immunocytokine L19-IL2:An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses [PDF]

, 2018
Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti-tumour effect.
Ludwig J. Dubois, Evert J. Van Limbergen, Dario Neri, Rianne Biemans, Ala Yaromina, Neri, Dario; id_orcid, Lieuwes, Natasja G., Neri, Dario, Olivo Pimentel, Veronica, Biemans, Rianne, Lambin, Philippe, Nicolle H. Rekers, Rekers, Nicolle H., Dubois, Ludwig J., Natasja G. Lieuwes, Wilfred T. V. Germeraad, Philippe Lambin, Veronica Olivo Pimentel, Van Limbergen, Evert J., Yaromina, Ala, Germeraad, Wilfred T. V., Germeraad, Wilfred T.V., Zegers, Catharina M. L., Zegers, Catharina M.L., Catharina M. L. Zegers, Pimentel, Veronica Olivo, Olivo Pimentel V, Zegers CML, Biemans R, Lambin P, Dubois LJ, Yaromina A, Lieuwes NG, Van Limbergen EJ, Neri D, Germeraad WTV, Rekers NH   +36 more
core   +1 more source

Combination Therapy of Immunocytokines with Ipilimumab: A Cure for Melanoma? [PDF]

Journal of Investigative Dermatology, 2013
Although biological therapy has shown promising clinical responses in many cancers including metastatic melanoma, only a subset of patients has shown marked regression of lesions. In most patients, systemic administration of biological therapies with cytokines is associated with severe toxicities.
Wang, Tao, Somasundaram, Rajasekharan, Herlyn, Meenhard   +2 more
openaire   +2 more sources

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy

, 2018
Purpose: Optimal dosing is critical for immunocytokine-based cancer immunotherapy to maximize efficacy and minimize toxicity. Cergutuzumab amunaleukin (CEA-IL2v) is a novel CEA-targeted immunocytokine.
Stefan Evers, Tapan Nayak, Volker Teichgräber, Alex Phipps, Jehad Charo, Christophe Boetsch, Hans Peter Grimm, Jean Tessier, Benjamin Ribba, Christian Klein, Pavel Pisa, Jean Eric Charoin   +11 more
core   +1 more source

Cytokine Engineering Approaches for Regenerative Medicine

Advanced Therapeutics, Volume 8, Issue 9, September 2025.
Engineered cytokines represent a powerful strategy to promote tissue repair and regeneration by precisely modulating immune responses. This review highlights recent advances in cytokine engineering, including strategies to enhance half‐life, improve tissue and cell targeting, and control receptor signaling.
Shiyi Li, Wenhao You, Mikaël M. Martino
wiley   +1 more source

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12 [PDF]

, 2017
Proinflammatory cytokines have been used for several years in patients with advanced cancer but their administration is typically associated with severe toxicity hampering their application to therapeutically active regimens. This problem can be overcome
Sommavilla, Roberto, Pasche, Nadine, Roesli, Christoph, Kaspar, Manuela, Villa, Alessandra, Giovannoni, Leonardo, Trachsel, Eveline, Neri, Dario   +7 more
core  

Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana

, 2016
Anti-CD20 murine or chimeric antibodies (Abs) have been used to treat non-Hodgkin lymphomas (NHLs) and other diseases characterized by overactive or dysfunctional B cells.
Benvenuto, E., Marusic, C., Novelli, F., Donini, M., Pioli, C.   +4 more
core   +1 more source